EP4105240A1 - Chimeric antigen receptor and use thereof - Google Patents
Chimeric antigen receptor and use thereof Download PDFInfo
- Publication number
- EP4105240A1 EP4105240A1 EP21753498.1A EP21753498A EP4105240A1 EP 4105240 A1 EP4105240 A1 EP 4105240A1 EP 21753498 A EP21753498 A EP 21753498A EP 4105240 A1 EP4105240 A1 EP 4105240A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- car
- cells
- chimeric antigen
- antigen receptor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 67
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 claims abstract description 65
- 108010025838 dectin 1 Proteins 0.000 claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 230000011664 signaling Effects 0.000 claims abstract description 32
- 230000002441 reversible effect Effects 0.000 claims abstract description 29
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 22
- 230000003834 intracellular effect Effects 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 125
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 25
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 20
- 102000004127 Cytokines Human genes 0.000 claims description 17
- 108090000695 Cytokines Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 13
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 13
- 102100037850 Interferon gamma Human genes 0.000 claims description 12
- 108010074328 Interferon-gamma Proteins 0.000 claims description 12
- 239000012636 effector Substances 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- 230000002194 synthesizing effect Effects 0.000 claims description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 238000001308 synthesis method Methods 0.000 claims description 6
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 5
- 208000025113 myeloid leukemia Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 53
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 20
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 20
- 230000000259 anti-tumor effect Effects 0.000 description 16
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 230000001086 cytosolic effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 101000635806 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Probable Rubredoxin-1 Proteins 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 10
- -1 FcR Proteins 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- 230000004940 costimulation Effects 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000011357 CAR T-cell therapy Methods 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 229950009579 axicabtagene ciloleucel Drugs 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000002101 lytic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108090000342 C-Type Lectins Proteins 0.000 description 4
- 102000003930 C-Type Lectins Human genes 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 102100022339 Integrin alpha-L Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102000017578 LAG3 Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000009126 molecular therapy Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 102100039904 Integrin alpha-D Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 108010059297 beta-glucan receptor Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100040839 C-type lectin domain family 6 member A Human genes 0.000 description 1
- 101710125370 C-type lectin domain family 6 member A Proteins 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 1
- 101150001713 Klre1 gene Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010052006 Mitogen Receptors Proteins 0.000 description 1
- 102000018656 Mitogen Receptors Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 108700004894 idecabtagene vicleucel Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 201000007426 ovarian cystadenocarcinoma Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Definitions
- the present invention belongs to the field of biomedicine, and particularly relates to a chimeric antigen receptor and use thereof.
- T cell immunotherapy has undergone a series of evolutionary processes.
- T cell activation mediated by a 1st generation CAR is accomplished by tyrosine-based activation motifs on CD3v or FceRIg.
- antitumor activity of T cells engineered by the 1st generation CAR is limited in vivo, resulting in T cell apoptosis due to reduced T cell proliferation.
- a 2nd generation CAR is added with a new intracellular costimulatory signal, such as 4-1BB or CD28.
- the 2nd generation CAR shows unchanged antigen specificity, increased T cell proliferation and cytokine secretion, increased anti-apoptotic protein secretion, and delayed cell death.
- Existing CAR-T cell immunotherapy has achieved remarkable progress in treating hematological malignancies, but limited success was observed in treating solid tumors.
- the progress of the CAR-T cell immunotherapy in treating hematological malignancies includes treating non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), multiple myeloma (MM) and chronic lymphoblastic leukemia (CLL). So far, the objective response rate (ORR) in CD19-specific or BCMA-specific CAR-T clinical trials ranges from 48% to 95%.
- the experiment team of the present invention designed a novel 2nd generation CAR-T cell engineered by incorporation of dectin-1 into a 2nd generation CAR structure as a costimulatory signaling domain and assessed function and antitumor activity of the engineered novel 2nd generation CAR-T cell, and thus to address at least one of the above problems.
- one of objectives of the present invention is to provide a novel 2nd generation CAR structure.
- a chimeric antigen receptor comprising an extracellular domain, a transmembrane domain and an intracellular domain, wherein the transmembrane domain and the intracellular domain of the chimeric antigen receptor form a costimulatory signaling domain, and the costimulatory signaling domain comprises a full length or a fragment of an amino acid sequence encoding a reverse dectin-1.
- the extracellular domain comprises a single-chain antibody targeting to CD19 or HER2.
- the chimeric antigen receptor further comprises a CD8 ⁇ hinge region, a reverse dectin-1 transmembrane domain, a reverse dectin-1 intracellular signaling domain and a CD3 ⁇ intracellular signaling domain which are connected in sequence.
- amino acid sequence encoding the reverse dectin-1 is shown in SEQ ID NO:3.
- a lentiviral vector comprising any one of the above chimeric antigen receptors.
- the lentiviral vector comprises pCLK, psPAX2 or pMD2.0G.
- One of objectives of the present invention is also to provide a CAR-T cell and use thereof, wherein the CAR-T cell is engineered by the above novel 2nd generation CAR.
- a CAR-T cell expressing the above chimeric antigen receptor is shown in FIG. 1 .
- the tumor comprises hematological tumors and solid tumors.
- the tumor comprises large B-cell lymphoma, B-cell lymphoma, non-Hodgkin lymphoma, myelogenous leukemia, lymphoblastic leukemia, breast cancer, gastric cancer, esophageal cancer or ovarian cancer.
- the CAR-T cell can stimulate secretion of effector cytokine.
- the effector cytokine comprises IFN- ⁇ , TNF- ⁇ and IL-6.
- the CAR-T cell upon being stimulated, display phenotype of a central memory T cell.
- the tumor comprises hematological tumors and solid tumors.
- the tumor comprises large B-cell lymphoma, B-cell lymphoma, non-Hodgkin lymphoma, myelogenous leukemia, lymphoblastic leukemia, breast cancer, gastric cancer, esophageal cancer or ovarian cancer.
- the objective of the present invention is also to provide a synthesis method for the above chimeric antigen receptor.
- a synthesis method for the above chimeric antigen receptor comprising the following steps: (1) synthesizing a gene sequence of the reverse dectin-1 transmembrane domain - reverse dectin-1 intracellular domain or a gene sequence of the reverse dectin-1 transmembrane domain - CD3 ⁇ intracellular signaling domain; (2) synthesizing primers according to a target, and synthesizing a gene sequence of the chimeric antigen receptor by an overlapping PCR method.
- the step (2) specifically comprises: first using primers F1 and R1 to expand a bound gene sequence of the extracellular domain and the CD8 ⁇ hinge region, then using primers F2 and R2 to expand the gene sequence of the reverse dectin-1 transmembrane domain - CD3 ⁇ intracellular signaling domain, and finally using the bound gene sequence of the extracellular domain and the CD8 ⁇ hinge region as well as the gene sequence of the reverse dectin-1 transmembrane domain - CD3 ⁇ intracellular signaling domain as templates and using F1 and R2 as primers to synthesize the gene sequence of the chimeric antigen receptor.
- primer F1 is shown in SEQ ID NO:7
- R1 is shown in SEQ ID NO:8
- F2 is shown in SEQ ID NO:9
- R2 is shown in SEQ ID NO:10.
- a method for synthesizing a gene sequence of the reverse dectin-1 transmembrane domain - reverse dectin-1 intracellular domain is the same.
- the present invention provides a novel 2nd generation CAR structure using a reverse dectin-1 as a costimulatory signaling domain and a CAR-T cell prepared thereby.
- the novel CAR design influences T cell functions through dectin-1 costimulation, such as enhanced cytokine secretion and lytic capacity of a variety of cytokines (including IFN- ⁇ , TNF- ⁇ and IL-6), reduced exhaustion potential, increased cell expansion and distinct antitumor activity.
- novel CAR-T cells provided by the present invention are effective against a variety of solid tumors and hematological malignancies.
- the term "about”, typically means +/-5% of the stated value, more typically +/-4% of the stated value, more typically +/-3% of the stated value, more typically, +/-2% of the stated value, even more typically +/-1% of the stated value, and even more typically +/-0.5% of the stated value.
- RD-1 is a reverse dectin-1, with an amino acid sequence of "GLVVAIVLIVLCLIGLIVAILRWPPSAACSGKESVVAIRTNSQSDFHLQTYGDE DLNELDPHYEM", as shown in SEQ ID NO:3; whereas an amino acid sequence of a dectin-1 is "MEYHPDLENLDEDGYTQLHFDSQSNTRTAVVSEKGSCAASPPWRLIAVILGI LCLVILVIAVVLG", as shown in SEQ ID NO:4.
- An amino acid sequence of an "RD-1 intracellular domain” is "RWPPSAACSGKESVVAIRTNSQSDFHLQTYGDEDLNELDPHYEM”, as shown in SEQ ID NO:1; and an amino acid sequence of an "RD-1 transmembrane domain” is "GLVVAIVLIVLCLIGLIVAIL”, as shown in SEQ ID NO:2.
- a dectin-1 in a CAR structure refers to a reverse dectin-1.
- HEK-293T cells were transfected with the following plasmids as detailed previously: the appropriate CAR-encoding plasmids, psPAX2 and pMD2.0G (Invitrogen). The medium was changed 12 h after transfection. The supernatant was harvested and spun to get rid of cell debris. The supernatant was filtered and concentrated by ultracentrifugation at 19,700 rpm for 2 h. The supernatant was discarded. The lentiviral pellet was dissolved in PBS medium and the concentrated lentivirus was stored at -80°C. The concentrated lentivirus titers were measured by quantitative real time polymerase chain reaction (Q-RT-PCR).
- Q-RT-PCR quantitative real time polymerase chain reaction
- PBMCs Peripheral Blood Mononuclear Cells
- PBMCs were cultured in X-VIVO 15 medium (Sigma-Aldrich, Cat:10771) with 5% human serum (Sigma-Aldrich, H4522) and 100 U/ml recombinant human IL-2 (rhIL-2) (PeproTech, NJ, USA. Cat: 200-02-10). PBMCs were stimulated with anti-CD3/CD28 magnetic beads (Gibco, Thermo Fisher, Waltham, MA. Cat: 11131D). After 24 h, T cells were cultured with the lentivirus at a multiplicity of infection (MOI) of 5 for 48 h, and then the cells were washed and cultured in the T cell medium. Transduction efficiency was determined by CAR expression measured by a flow cytometry.
- MOI multiplicity of infection
- Transduction efficiency and associated CAR protein expression were evaluated using biotin-SP-conjugated AffiniPure Goat Anti-Mouse IgG, F(ab')2 Fragment Specific (Cat: 120962, Jackson Immune Research) with PE-streptavidin (Cat: 405203, BD Biosciences).
- anti-CD3-FITC (clone: HIT3a, Cat: 300306, Biolegend), anti-CD8-APC (clone: HIT8a, Cat: 300912, Biolegend), anti-CD4-PE (clone: RPA-T4, Cat: 300508, Biolegend), anti-CD45ROPE (BD Biosciences, clone: UCHL1, Cat: 555493), antiCD62L-APC (BD Biosciences, clone: DREG-56, Cat: 559772), anti-PD-1-APC (clone: EH12.2H7, Cat: 329908, Biolegend), anti-CTLA-4-APC (Cat: 369612, Biolegend), anti-LAG3-APC (Cat: 369212, Biolegend), and anti-TIM3- APC (Cat: 345012, Biolegend).
- Target cells (NALM6, K562, SK-OV-3 or MDA-MB-468, at 1 ⁇ 10 5 cells/well) were seeded in 96-well plates and incubated at 37°C with 5% CO 2 overnight. After that, CAR-T cells were added at an effector/target ratio (E:T) of 5 or 10. The CAR-T cell number was normalized by transduction efficiency. Supernatants were collected 24 h after co-culture with the target cells.
- E:T effector/target ratio
- ELISA kits for cytokine assay from Invitrogen were used to quantify IFN- ⁇ , TNF- ⁇ and IL-6.
- RTCA Real-time cytotoxicity assays
- CAR-T cells The cytotoxic effect of CAR-T cells was measured by the real-time cytotoxicity assay (ACEA Bioscience, Inc. xCELLigence RTCA SP).
- SK-OV-3 or MDA-MB-468 cells at 1 ⁇ 10 4 cells/well were cultured in an E-plate 96 for -24 h.
- CAR-T cells (hH8-BBz and hHD-Dz) or mock T cells were added to the plates at an E:T ratio of 10. Data were acquired and analyzed according to the protocols specified by the manufacturers (ACEA 162 Bioscience, Inc. RTCA Software 2.1).
- mice Six-week old female B-NSG (NOD-Prkdcscid IL2rgtm1/Bcgen) mice were used in this study. Each mouse received an i.p. injection of 2 ⁇ 10 6 SK-OV-3-luc cells.
- the SK-OV-3-luc cells were obtained by engineering design of SK-OV-3 cells, which can express luciferase and display tumor growth through fluorescence signals in a subsequent tumor bioluminescence imaging experiment.
- Tumors were allowed to grow for 3 days, and then each mouse received an i.p. injection of 1 ⁇ 10 7 CAR-T cells (hH8-BBz, hHD-Dz or mock). After 3 additional days, another i.p. injection of the CAR-T cells was given to individual mouse.
- Bioluminescent imaging (BLI) for tumors was performed on scheduled days (day 3, day 10, day 17, day 24, day 31 and day 55) by IVIS (in vivo imaging system). Tumor fluxes (photon/s/cm 2 /steradian) were quantified by measuring the photon signal within a delineated region of interest (ROI) encompassing.
- Living Image software v2.50, Xenogen; Caliper Life Sciences
- Kaplan-Meier survival data were analyzed using a log rank (Mantel-Cox) test. Data were transformed when needed to normalize variance. Symbols indicate statistical significance as follows: ⁇ P ⁇ 0.05; ⁇ P ⁇ 0.01 and ⁇ P ⁇ 0.001.
- novel 2nd generation CAR constructs were designed through the combination of scFv domains targeting either CD19 or HER2 epitope with the dectin-1 TM, dectin-1 and CD3 ⁇ ICDs ( Fig. 1A ).
- Two more CAR constructs were generated with the components of the most popular 2nd generation CAR structure (human CD8 ⁇ TM with 4-1BB and CD3 ⁇ ICDs). All CAR constructs were well expressed on the surface of T cells ( Fig. 1B ).
- the anti-HER2 CARs the hH8-BBz (4-1BB) CAR expression ratio was 49.61%, and the hHD-Dz (dectin-1) CAR expression ratio was 46.17%.
- CAR-T cells typically, a later effector function by CAR-T cells can be assessed by cytokine secretion. Therefore, the impacts of dectin-1 as a costimulatory signaling molecule on cytokine release from the new CAR-T cells were evaluated following exposure to tumor cells that express either HER2 or CD19.
- the released effector cytokines, including IFN- ⁇ , TNF- ⁇ and IL-6, by anti-HER2 or anti-CD19 CAR-T cells increased significantly with incorporating the dectin-1 signaling domain in the target positive cell lines (SK-OV-3 and NALM6) ( Fig. 2A , 2B and 2C ).
- Anti-HER2 CAR-T cells in this study showed no significant increase of cytokine production against MD-MB-468 (negative cell lines) ( Fig. 2A , 2B and 2C ).
- the hHD-Dz CAR-T cells showed higher levels of IFN- ⁇ than hH8-BBz CAR-T cells; in contrast, the hH8-BBz CAR-T cells secreted more TNF- ⁇ ( Fig. 2A , 2B and 2C ).
- the h19D-Dz CAR-T cells produced similar levels of IFN- ⁇ and TNF- ⁇ to the h198-BBz CART cells ( Fig. 2A , 2B and 2C ).
- the phenotype and exhaustion marker expression of both anti-HER2 CAR-T cells and mock T cells were analyzed after a 7-day period of cell expansion ( Fig. 3 ).
- the hHD-Dz, hH8-BBz CAR-T and mock T cells showed similar percentage of CD4 + or CD8 + T cells ( Fig. 3A ). Although comparable percentage of effector memory T (T EM , CD45RO+ CD62L-) was observed in the hHD-Dz and hH8-BBz CAR-T cells, the hHD-Dz CAR-T cells showed a higher percentage of central memory T cells (T CM , CD45RO+ CD62L+) than the hH8-BBz CAR-T cells ( Fig. 3A ).
- inhibitory receptors including PD-1, CTLA-4, TIM3 and LAG3, was assessed for the anti-HER2 CAR-T cells ( Fig. 3B ) in the present invention.
- the dectin-1 signaling domain in the novel CAR-T cells may result in distinct phenotype and exhaustion marker expression, and discrete T cell proliferation potential.
- the log rank (Mantel-Cox) test demonstrated a statistically significant difference in the survival rates between either anti-HER2 CAR-T cell group and mock T cell group. Moreover, 100% of mice in the hHD-Dz CAR-T cell group were alive by day 55, and the hH8-BBz CAR-T group showed longer overall survival ( Fig. 4B ).
- the embodiment further provides a costimulatory signaling domain of a chimeric antigen receptor, wherein the costimulatory signaling domain comprises an RD-1 intracellular domain.
- the costimulatory signaling domain comprises CD3 ⁇ .
- the RD-1 intracellular domain comprises an amino acid sequence of SEQ ID NO:1 or an amino acid sequence having not less than 90% identity with SEQ ID NO:1.
- the costimulatory signaling domain further comprises one or more of CD3, CD4, CD8, FcR, DAP10, DAP12, CD27, CD28, CD137, CD134, ICOS, OX40, CD30, CD40, PD-1, LFA-1, CD2, CD7, LIGHI, NKG2C, B7-H3, CD83-specific binding ligand, CDS, ICAM-1, GITR, BAFFR, HVEM (IGHTR), SLAMF7, NKp80 KLRE1, CD160, CD19, CD83, IL-2R ⁇ , IL-R ⁇ , IL-7R ⁇ , ITGA4, VLA1, CD49 ⁇ , ITGA4, IA4, CD49D, ITGA6, LA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11 ⁇ , LFA-1, ITGAM, CDIIB, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7 TA
- the embodiment further provides a chimeric antigen receptor comprising the above-mentioned costimulatory signaling domain.
- the chimeric antigen receptor comprises an antigen recognition domain, a CD8 ⁇ hinge region, a transmembrane domain, an RD-1 intracellular domain and CD3 ⁇ which are connected in sequence.
- an amino acid sequence comprised in the transmembrane domain is capable of anchoring the chimeric antigen receptor to a cell membrane.
- the transmembrane domain comprises an RD-1 transmembrane domain.
- the RD-1 transmembrane domain comprises an amino acid sequence of SEQ ID NO:2 or an amino acid sequence having not less than 90% identity with SEQ ID NO:2.
- the antigen recognition domain is a HER2 binding domain.
- the chimeric antigen receptor comprises an amino acid sequence of SEQ ID NO:5.
- the antigen recognition domain is a CD19 binding domain.
- the chimeric antigen receptor comprises an amino acid sequence of SEQ ID NO:6.
- the embodiment further provides a synthesis method of the above-mentioned chimeric antigen receptor, wherein the method comprises the following steps: step (1) synthesizing a gene sequence of RD-1-CD3 ⁇ ; step (2) synthesizing a gene sequence of the chimeric antigen receptor.
- the step (2) specifically comprises: first using primers F1 and R1 to expand a bound gene sequence of the antigen recognition domain and the CD8 ⁇ hinge region, then using primers F2 and R2 to expand the gene sequence of RD-1-CD3 ⁇ , and finally using the bound gene sequence of the antigen recognition domain and the CD8 ⁇ hinge region as well as the gene sequence of RD-1-CD3 ⁇ as templates and using F1 and R2 as primers to synthesize the gene sequence of the chimeric antigen receptor.
- primer F1 is shown in SEQ ID NO:7
- R1 is shown in SEQ ID NO:8
- F2 is shown in SEQ ID NO:9
- R2 is shown in SEQ ID NO:10.
- An amino acid sequence of the synthesized (anti-HER2 scFV)-(CD8 ⁇ hinge)-(RD-1TM+Cytoplasmic)-(CD3 ⁇ ) is SEQ ID NO:5.
- the embodiment further provides a recombinant plasmid vector constructed by the above-mentioned chimeric antigen receptor and an expression vector.
- the expression vector is a pCLK vector.
- the embodiment further provides a construction method of the above-mentioned recombinant plasmid vector, wherein the construction method comprises: using Mlu I and Spe I as restriction sites to connect genes of the chimeric antigen receptor with the expression vector, and thus to obtain the recombinant plasmid vector.
- the embodiment further provides an immune cell modified by the above-mentioned chimeric antigen receptor.
- the immune cell is T lymphocyte.
- the immune cell also includes one or more of B lymphocyte, K lymphocyte and NK lymphocyte.
- the embodiment further provides a method for obtaining the above-mentioned immune cell, wherein the method comprises the following steps: using Mlu I and Spe I as restriction sites to connect genes of the chimeric antigen receptor with an expression vector, and thus to obtain a recombinant plasmid vector; transfecting the recombinant plasmid vector and packaging plasmids together into cultured cells for culturing, thus to obtain recombinant virus particles; and using the recombinant virus particles to modify the immune cell.
- method of the modification comprises: using a virus vector system or non-virus vector system.
- the virus vector system includes one or more of a retroviral vector, a lentiviral vector, an adenovirus vector, an adeno-associated virus vector and a sendai virus vector.
- the purpose of the present invention is to further provide an application of the above-mentioned immune cell in preparation of an antitumor drug composition.
- the antitumor drug composition further comprises a chemical drug.
- the antitumor drug composition is an antitumor drug against breast cancer and/or ovarian cancer.
- the embodiment further provides a composition comprising the above-mentioned chimeric antigen receptor, wherein the composition further comprises one or more of a ⁇ -glucan receptor, Syk, CR3 and CD11b bound to the costimulatory signaling domain.
- Fig. 6 is an expression assay of a human T cell transfected by the conventional 2nd generation CAR genes, wherein the primary antibody used is a biotin-labeled goat anti-mouse Fab monoclonal antibody, and the secondary antibody used is a PE-labeled anti-streptavidin antibody (for flow cytometry).
- the first lane is a T cell transfected with empty virus, and the second lane is a T cell transfected with CAR genes.
- hH8-BBz represents the conventional 2nd generation CAR genes (anti-HER2 scFV)-(CD8 ⁇ hinge+TM)-(4-1BB)-(CD3 ⁇ )).
- Fig. 7 is an expression assay of a human T cell transfected by the novel 2nd generation CAR genes, wherein the primary antibody used is a biotin-labeled goat anti-mouse Fab monoclonal antibody, and the secondary antibody used is a PE-labeled anti-streptavidin antibody (for flow cytometry).
- the first lane is a T cell transfected with empty virus, and the second lane is a T cell transfected with CAR genes.
- hHD-Dz represents the novel 2nd generation CAR genes (anti-HER2 scFV)-(CD8 ⁇ hinge)-(RD-1TM+Cytoplasmic)-(CD3 ⁇ )).
- CD19 or HER2-targeting scFv domains were coupled to 4-1BB or dectin-1 signaling ICDs by our experiment team to construct four different 2nd generation CARs.
- Experiment data revealed that the novel CAR design influenced T cell functions through dectin-1 costimulation in both in vitro and in vivo experiments, such as enhanced cytokine secretion and lytic capacity, reduced exhaustion potential, and increased cell expansion and distinct antitumor activity.
- T CM cells are more important than T EM cells in the adoptive immunotherapies.
- T CM and distinct exhaustion marker expression in the hHD-Dz CAR-T cells may suggest that the new CAR-T cells can be less influenced by the tumor immunosuppressive microenvironment through the dectin-1 costimulatory signaling in the solid tumors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- . The present application claims priority from Chinese invention patent application
CN2020100907495 "A COSTIMULATORY SIGNALING DOMAIN OF A CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF" filed on February 13, 2020 - . The present invention belongs to the field of biomedicine, and particularly relates to a chimeric antigen receptor and use thereof.
- .Chimeric antigen receptor (CAR) T cell immunotherapy, as a promising tumor therapy strategy, has undergone a series of evolutionary processes. T cell activation mediated by a 1st generation CAR is accomplished by tyrosine-based activation motifs on CD3v or FceRIg. However, antitumor activity of T cells engineered by the 1st generation CAR is limited in vivo, resulting in T cell apoptosis due to reduced T cell proliferation. A 2nd generation CAR is added with a new intracellular costimulatory signal, such as 4-1BB or CD28. Compared with the 1st generation CAR, the 2nd generation CAR shows unchanged antigen specificity, increased T cell proliferation and cytokine secretion, increased anti-apoptotic protein secretion, and delayed cell death. Existing CAR-T cell immunotherapy has achieved remarkable progress in treating hematological malignancies, but limited success was observed in treating solid tumors.
- . The progress of the CAR-T cell immunotherapy in treating hematological malignancies includes treating non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), multiple myeloma (MM) and chronic lymphoblastic leukemia (CLL). So far, the objective response rate (ORR) in CD19-specific or BCMA-specific CAR-T clinical trials ranges from 48% to 95%. Two CAR-T cell products, specific to the B lymphoma, Axicabtagene Ciloleucel (KTE-C19, Kite Pharma) and Tisagenlecleuce (CTL019, Novartis), were approved by the U.S. Food and Drug Administration (US FDA) in 2017. In a
phase 1/2 trial with Axicabtagene ciloleucel, 2-year follow-up data, involving 108 patients with the refractory large B-cell lymphoma, showed that 83% of patients had an objective response (OR), and 58% of them had a complete response (CR), with a median follow-up of 15.4 months (IQR 13.7-17.3). This suggests that CAR-T cell therapy can maintain a long-term remission. But, there are a lot of challenges in the application of CAR-T cell therapy in the solid tumors, such as lack of appropriate tumor-specific antigen, inhibition of tumor microenvironment, and insufficient CAR-T cell localization and persistence. In addition, continuous antigen exposure can result in CAR-T cell exhaustion, and then compromising the effectiveness of CAR-T cells against tumors. Therefore, new approaches are necessary to design CARs in the treatment of solid tumors. - . Dectin-1, i.e. CLEC-7A, is a new subgroup of C-type lectin receptors (CLRs). Dectin-1 comprises an extracellular domain, a transmembrane domain and an intracellular domain. The extracellular domain of dectin-1 has been utilized as the scFv of CAR-T cells to target fungus. Dectin-1 is not only predominantly expressed on myeloid cells, including neutrophils, monocytes, dendritic cells and macrophages, but also on some subsets of human T cells and B cells. Dectin-1 plays an important role in tumor growth and metastasis by activating the NK cells. Dectin-1 can also regulate various cellular responses, such as DC maturation, antigen presentation and production of cytokine and chemokine. In addition, dectin-1 can directly induce innate immune memory, and influence the development of CD8, CD4, T and B cells in theory.
- . In conclusion, the experiment team of the present invention designed a novel 2nd generation CAR-T cell engineered by incorporation of dectin-1 into a 2nd generation CAR structure as a costimulatory signaling domain and assessed function and antitumor activity of the engineered novel 2nd generation CAR-T cell, and thus to address at least one of the above problems.
- . In view of this, one of objectives of the present invention is to provide a novel 2nd generation CAR structure.
- . A chimeric antigen receptor, comprising an extracellular domain, a transmembrane domain and an intracellular domain, wherein the transmembrane domain and the intracellular domain of the chimeric antigen receptor form a costimulatory signaling domain, and the costimulatory signaling domain comprises a full length or a fragment of an amino acid sequence encoding a reverse dectin-1.
- . Further, the extracellular domain comprises a single-chain antibody targeting to CD19 or HER2.
- . Further, the chimeric antigen receptor further comprises a CD8α hinge region, a reverse dectin-1 transmembrane domain, a reverse dectin-1 intracellular signaling domain and a CD3ζ intracellular signaling domain which are connected in sequence.
- . Further, the amino acid sequence encoding the reverse dectin-1 is shown in SEQ ID NO:3.
- . Further, an amino acid sequence encoding the reverse dectin-1 transmembrane domain is shown in SEQ ID NO:2.
- . Further, an amino acid sequence encoding the reverse dectin-1 intracellular signaling domain is shown in SEQ ID NO:1.
- . A lentiviral vector comprising any one of the above chimeric antigen receptors.
- . Further, the lentiviral vector comprises pCLK, psPAX2 or pMD2.0G.
- . One of objectives of the present invention is also to provide a CAR-T cell and use thereof, wherein the CAR-T cell is engineered by the above novel 2nd generation CAR.
- . A CAR-T cell expressing the above chimeric antigen receptor.
- . An antitumor drug, comprising the above CAR-T cell and a pharmaceutically acceptable excipient and/or adjuvant.
- . Further, the tumor comprises hematological tumors and solid tumors.
- . Further, the tumor comprises large B-cell lymphoma, B-cell lymphoma, non-Hodgkin lymphoma, myelogenous leukemia, lymphoblastic leukemia, breast cancer, gastric cancer, esophageal cancer or ovarian cancer.
- . Use of the above CAR-T cell in preparation of an antitumor drug.
- . Further, the CAR-T cell can stimulate secretion of effector cytokine.
- . Further, the effector cytokine comprises IFN-γ, TNF-α and IL-6.
- . Further, the CAR-T cell, upon being stimulated, display phenotype of a central memory T cell.
- . Further, the tumor comprises hematological tumors and solid tumors.
- . Further, the tumor comprises large B-cell lymphoma, B-cell lymphoma, non-Hodgkin lymphoma, myelogenous leukemia, lymphoblastic leukemia, breast cancer, gastric cancer, esophageal cancer or ovarian cancer.
- . The objective of the present invention is also to provide a synthesis method for the above chimeric antigen receptor.
- . A synthesis method for the above chimeric antigen receptor, comprising the following steps: (1) synthesizing a gene sequence of the reverse dectin-1 transmembrane domain - reverse dectin-1 intracellular domain or a gene sequence of the reverse dectin-1 transmembrane domain - CD3ζ intracellular signaling domain; (2) synthesizing primers according to a target, and synthesizing a gene sequence of the chimeric antigen receptor by an overlapping PCR method.
- . Further, the step (2) specifically comprises: first using primers F1 and R1 to expand a bound gene sequence of the extracellular domain and the CD8α hinge region, then using primers F2 and R2 to expand the gene sequence of the reverse dectin-1 transmembrane domain - CD3ζ intracellular signaling domain, and finally using the bound gene sequence of the extracellular domain and the CD8α hinge region as well as the gene sequence of the reverse dectin-1 transmembrane domain - CD3ζ intracellular signaling domain as templates and using F1 and R2 as primers to synthesize the gene sequence of the chimeric antigen receptor.
- . Further, the primer F1 is shown in SEQ ID NO:7, R1 is shown in SEQ ID NO:8, F2 is shown in SEQ ID NO:9, and R2 is shown in SEQ ID NO:10.
- . A method for synthesizing a gene sequence of the reverse dectin-1 transmembrane domain - reverse dectin-1 intracellular domain is the same.
- . The present invention provides a novel 2nd generation CAR structure using a reverse dectin-1 as a costimulatory signaling domain and a CAR-T cell prepared thereby. In vivo and in vitro experiment results of the present invention reveal that the novel CAR design influences T cell functions through dectin-1 costimulation, such as enhanced cytokine secretion and lytic capacity of a variety of cytokines (including IFN-γ, TNF-α and IL-6), reduced exhaustion potential, increased cell expansion and distinct antitumor activity. Experiments prove that novel CAR-T cells provided by the present invention are effective against a variety of solid tumors and hematological malignancies.
- . To make the embodiments of the present invention or the technical solutions in the prior art clearer, the drawings required to be used in the description of the embodiments or the prior art will be briefly introduced below. It is obvious that the drawings described below are some embodiments of the present invention, and that other drawings can be obtained from these drawings for those of ordinary skill in the art without making inventive effort.
- .
Fig. 1 shows CAR constructs and expression: (A) Schematic representation of chimeric receptors that comprise the single-chain fragment that binds to HER2 or CD19 and differ in the transmembrane and intracellular domains; (B) Surface expression of the hH8-BBz CAR and the hHD-Dz CAR, the h198-BBz CAR and the h19D-Dz CAR on the human T cells; - .
Fig. 2 shows in vitro cytokine production and cytotoxicity of the CAR-T cells, (A) IFN-γ, (B) IL-6 and (C) TNF-α quantified by ELISA in supernatants from four different CAR-T cells or mock T cells co-cultured with target positive or negative tumor cells overnight (E:T = 10:1 or 5:1) (n = 3/group); statistical analysis is performed by one-way ANOVA, followed by Tukey's posttest analysis; significance is considered P < 0.05; (D) RTCA analysis shows T cell lytic capacity (n = 4/group); - .
Fig. 3 shows phenotype, exhaustion marker expression and CAR expression of the HER2 specific CAR-T cells: (A) Flow cytometer density plots of phenotypic profile of each CAR-T cell: cells with either CD3, CD4, or CD8, or a naive (TN) (CD45RA-/CD62L-) central memory T cells (TCM) (CD45RO+/CD62L+) or effector memory (TEM) (CD45RO+/CD62L-); (B) Flow cytometer density plots of inhibitory molecules of each CAR-T cell: cells with either PD-1, or LAG3, or CTLA-4, or TIM3; (C) The CAR expression of the hH8-BBz CAR-T cells and the hHD-Dz CAR-T cells with time measured by flow cytometry; - .
Fig. 4 shows in vivo antitumor activity of the HER2 specific CAR-T cells: (A) In vivo live imaging of the SK-OV-3-luc tumor bearing model (n = 4/group); (B) Kaplan-Meier analysis of the overall survival rate for each group; - .
Fig. 5 is a structural schematic diagram of a 2nd generation chimeric antigen receptor (RD-1) targeting to HER2; - .
Fig. 6 is an expression assay diagram of human T cells transfected by conventional 2nd generation CAR genes; - .
Fig. 7 is an expression assay diagram of human T cells transfected by novel 2nd generation CAR (RD-1) genes; and - .
Fig. 8 is an assay diagram of IFN-γ secretion of CAR-T cells (RD-1) targeting to HER2 positive tumor cells SKOV3 and HER2 negative tumor cells MDA-MB-468. - . To make the objective, the technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below in combination with drawings. It is obvious that the described embodiments are some of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without making inventive effort shall belong to the protection scope of the present invention.
- . The embodiments are for the purpose of better illustration of the present invention, but the contents of the present invention are not limited to the embodiments. Therefore, non-essential improvements and adjustments of the embodiments made by those skilled in the art according to the above-mentioned contents of the present invention still belong to the protection scope of the present invention.
- . It should be noted that the term "include", "comprise" or any variant thereof is intended to encompass nonexclusive inclusion so that a process, method, article or device including a series of elements includes not only those elements but also other elements which have been not listed definitely or an element(s) inherent to the process, method, article or device. Moreover, the expression "comprising a(n) ... " in which an element is defined will not preclude presence of an additional identical element(s) in a process, method, article or device comprising the defined element(s) unless further defined.
- . As used herein, the term "about", typically means +/-5% of the stated value, more typically +/-4% of the stated value, more typically +/-3% of the stated value, more typically, +/-2% of the stated value, even more typically +/-1% of the stated value, and even more typically +/-0.5% of the stated value.
- . Throughout this application, embodiments of this invention may be presented with reference to a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as "from 1 to 6" should be considered to have specifically disclosed subranges such as "from 1 to 3", "from 1 to 4", "from 1 to 5", "from 2 to 4", "from 2 to 6", "from 3 to 6", etc.; as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- . "RD-1" is a reverse dectin-1, with an amino acid sequence of "GLVVAIVLIVLCLIGLIVAILRWPPSAACSGKESVVAIRTNSQSDFHLQTYGDE DLNELDPHYEM", as shown in SEQ ID NO:3; whereas an amino acid sequence of a dectin-1 is "MEYHPDLENLDEDGYTQLHFDSQSNTRTAVVSEKGSCAASPPWRLIAVILGI LCLVILVIAVVLG", as shown in SEQ ID NO:4. An amino acid sequence of an "RD-1 intracellular domain" is "RWPPSAACSGKESVVAIRTNSQSDFHLQTYGDEDLNELDPHYEM", as shown in SEQ ID NO:1; and an amino acid sequence of an "RD-1 transmembrane domain" is "GLVVAIVLIVLCLIGLIVAIL", as shown in SEQ ID NO:2. The inventor investigated that in preparation of a novel 2nd generation CAR, using the reverse dectin-1 as a costimulatory domain can efficiently produce and maintain activity and functions of the dectin-1 (i.e. can influence functions of T cells, enhance secretion and lytic capacity of a variety of cytokines (including IFN-γ, TNF-α and IL-6), reduce exhaustion potential, and increase cell expansion and significant antitumor activity). Therefore, unless otherwise specified herein, a dectin-1 in a CAR structure refers to a reverse dectin-1.
- .
- 1. Cell lines: all cell lines were obtained from the American Type Culture Collection (ATCC). The K562 (myelogenous leukemia) and NALM6 (lymphoblastic leukemia) were cultured in RPMI-1640 with heat-inactivated 10% fetal bovine serum (FBS) (PAN, Germany. Cat: ST30-3302), penicillin (Gibco, Thermo Fisher, Waltham, MA. Cat: SV30010) (100 U/mL) and streptomycin (Gibco, Thermo Fisher, Waltham, MA. Cat: SV30010) (100 ug/mL). The human cancer cell lines SK-OV-3 (ovarian cystadenocarcinoma) and MDA-MB-468 (breast cancer) were cultured in DMEM with heat-inactivated 10% FBS, penicillin (100 U/mL) and streptomycin (100 ug/mL). SK-OV-3 cells were also engineered to express luciferase.
- 2. Construction of plasmids encoding CARs
Anti-CD 19 or anti-HER2 CARs include a single-chain fragment variable (scFv) specific to CD19 (clone FMC63) or HER2 (clone 4D5). The scFv was followed by a human CD8α hinge region, then either a human CD8α transmembrane domain (TM), 4-1BB or CD3ζ intracellular domains (ICDs). CAR sequences are formed by overlapping PCR. Individual lentiviral plasmids encoding each CAR sequence was constructed using double enzymes digestion with the PCLK lentiviral vector. Four CAR sequences constructed were as follows:- 1) hH8-BBZ: HER2 scFv-CD8α(hinge + TM)-4-1BB-CD3ζ ICDs
- 2) hHD-DZ: HER2 scFv-CD8α hinge +Dectin-1(TM + cytoplasm) -CD3ζ ICDs
- 3) h198-BBZ: CD19 scFv-CD8α(hinge + TM)-4-1BB-CD3ζ ICDs
- 4) h19D-DZ: CD19 scFv-CD8α hinge +Dectin-1(TM + cytoplasm) -CD3ζ ICDs
- 3. Generation of lentiviral particles
HEK-293T cells (embryonic kidney cells) from ATCC were cultured in DMEM with heat-inactivated 10% fetal bovine serum (FBS) (PAN, Germany. Cat: ST30-3302), penicillin (100 U/mL) and streptomycin (Gibco, Thermo Fisher, Waltham, MA. Cat: SV30010) (100 ug/mL). - . To produce lentivirus-comprising supernatant, HEK-293T cells were transfected with the following plasmids as detailed previously: the appropriate CAR-encoding plasmids, psPAX2 and pMD2.0G (Invitrogen). The medium was changed 12 h after transfection. The supernatant was harvested and spun to get rid of cell debris. The supernatant was filtered and concentrated by ultracentrifugation at 19,700 rpm for 2 h. The supernatant was discarded. The lentiviral pellet was dissolved in PBS medium and the concentrated lentivirus was stored at -80°C. The concentrated lentivirus titers were measured by quantitative real time polymerase chain reaction (Q-RT-PCR).
- . Peripheral Blood Mononuclear Cells (PBMCs) were isolated from healthy donor blood by the Ficoll-hypaque density gradient (Lonza, Cat:04-418Q). All samples were obtained after informed consent and approval by the Ethics Committee of the State Key Laboratory of Biotherapy.
- . PBMCs were cultured in X-VIVO 15 medium (Sigma-Aldrich, Cat:10771) with 5% human serum (Sigma-Aldrich, H4522) and 100 U/ml recombinant human IL-2 (rhIL-2) (PeproTech, NJ, USA. Cat: 200-02-10). PBMCs were stimulated with anti-CD3/CD28 magnetic beads (Gibco, Thermo Fisher, Waltham, MA. Cat: 11131D). After 24 h, T cells were cultured with the lentivirus at a multiplicity of infection (MOI) of 5 for 48 h, and then the cells were washed and cultured in the T cell medium. Transduction efficiency was determined by CAR expression measured by a flow cytometry.
- . All flow cytometry assays were performed on a Novocyte flow cytometry (ACEA Biosicences, Inc.), and data were analyzed by novocyte express (ACEA Biosicences, Inc.).
- . Transduction efficiency and associated CAR protein expression were evaluated using biotin-SP-conjugated AffiniPure Goat Anti-Mouse IgG, F(ab')2 Fragment Specific (Cat: 120962, Jackson Immune Research) with PE-streptavidin (Cat: 405203, BD Biosciences).
- . The following antibodies were used for differentiation phenotype, and exhaustion marker assays:
. anti-CD3-FITC (clone: HIT3a, Cat: 300306, Biolegend), anti-CD8-APC (clone: HIT8a, Cat: 300912, Biolegend), anti-CD4-PE (clone: RPA-T4, Cat: 300508, Biolegend), anti-CD45ROPE (BD Biosciences, clone: UCHL1, Cat: 555493), antiCD62L-APC (BD Biosciences, clone: DREG-56, Cat: 559772), anti-PD-1-APC (clone: EH12.2H7, Cat: 329908, Biolegend), anti-CTLA-4-APC (Cat: 369612, Biolegend), anti-LAG3-APC (Cat: 369212, Biolegend), and anti-TIM3- APC (Cat: 345012, Biolegend). - . Target cells (NALM6, K562, SK-OV-3 or MDA-MB-468, at 1×105 cells/well) were seeded in 96-well plates and incubated at 37°C with 5% CO2 overnight. After that, CAR-T cells were added at an effector/target ratio (E:T) of 5 or 10. The CAR-T cell number was normalized by transduction efficiency. Supernatants were collected 24 h after co-culture with the target cells. ELISA kits for cytokine assay from Invitrogen (IFN-γ Cat: 88-7316-88, TNF-α Cat: 88-7346-88, and IL-6 Cat: 88-7066-88) were used to quantify IFN-γ, TNF-α and IL-6.
- . The cytotoxic effect of CAR-T cells was measured by the real-time cytotoxicity assay (ACEA Bioscience, Inc. xCELLigence RTCA SP). SK-OV-3 or MDA-MB-468 cells at 1×104 cells/well were cultured in an E-plate 96 for -24 h. CAR-T cells (hH8-BBz and hHD-Dz) or mock T cells were added to the plates at an E:T ratio of 10. Data were acquired and analyzed according to the protocols specified by the manufacturers (ACEA 162 Bioscience, Inc. RTCA Software 2.1).
- . Six-week old female B-NSG (NOD-Prkdcscid IL2rgtm1/Bcgen) mice were used in this study. Each mouse received an i.p. injection of 2×106 SK-OV-3-luc cells.
- . The SK-OV-3-luc cells were obtained by engineering design of SK-OV-3 cells, which can express luciferase and display tumor growth through fluorescence signals in a subsequent tumor bioluminescence imaging experiment.
- . Tumors were allowed to grow for 3 days, and then each mouse received an i.p. injection of 1×107 CAR-T cells (hH8-BBz, hHD-Dz or mock). After 3 additional days, another i.p. injection of the CAR-T cells was given to individual mouse. Bioluminescent imaging (BLI) for tumors was performed on scheduled days (
day 3,day 10, day 17, day 24, day 31 and day 55) by IVIS (in vivo imaging system). Tumor fluxes (photon/s/cm2/steradian) were quantified by measuring the photon signal within a delineated region of interest (ROI) encompassing. Living Image software (v2.50, Xenogen; Caliper Life Sciences) was used to demonstrate the BLI data. The data for survival analysis was established at the death of each mouse. - . Statistical plotting and analysis were performed using GraphPad Prism v6.01 (GraphPad Software Inc.) and SPSS V17. Data were expressed as the mean ± SD. One-way ANOVA was used for comparison of three groups in a single condition.
- . Kaplan-Meier survival data were analyzed using a log rank (Mantel-Cox) test. Data were transformed when needed to normalize variance. Symbols indicate statistical significance as follows: ∗ P < 0.05; ∗∗ P < 0.01 and ∗∗∗ P < 0.001.
- . In the present invention, novel 2nd generation CAR constructs were designed through the combination of scFv domains targeting either CD19 or HER2 epitope with the dectin-1 TM, dectin-1 and CD3ζ ICDs (
Fig. 1A ). Two more CAR constructs were generated with the components of the most popular 2nd generation CAR structure (human CD8α TM with 4-1BB and CD3ζ ICDs). All CAR constructs were well expressed on the surface of T cells (Fig. 1B ). As to the anti-HER2 CARs, the hH8-BBz (4-1BB) CAR expression ratio was 49.61%, and the hHD-Dz (dectin-1) CAR expression ratio was 46.17%. As to the anti-CD19 CARs, the h198-BBz (4-1BB) CAR expression ratio was 92.95%, and the h19D-Dz (dectin-1) CAR expression ratio was 95.07%. Although the expression of anti-HER2 CARs was lower than anti-CD19 CARs, there was no clear difference in the expression level of anti-HER2 or anti-CD19 CARs comprising different costimulatory signaling domains. - . Typically, a later effector function by CAR-T cells can be assessed by cytokine secretion. Therefore, the impacts of dectin-1 as a costimulatory signaling molecule on cytokine release from the new CAR-T cells were evaluated following exposure to tumor cells that express either HER2 or CD19.
- . The released effector cytokines, including IFN-γ, TNF-α and IL-6, by anti-HER2 or anti-CD19 CAR-T cells increased significantly with incorporating the dectin-1 signaling domain in the target positive cell lines (SK-OV-3 and NALM6) (
Fig. 2A ,2B and2C ). Anti-HER2 CAR-T cells in this study showed no significant increase of cytokine production against MD-MB-468 (negative cell lines) (Fig. 2A ,2B and2C ). In SK-OV-3 cell line, the hHD-Dz CAR-T cells showed higher levels of IFN-γ than hH8-BBz CAR-T cells; in contrast, the hH8-BBz CAR-T cells secreted more TNF-α (Fig. 2A ,2B and2C ). In NALM6 cell line, the h19D-Dz CAR-T cells produced similar levels of IFN-γ and TNF-α to the h198-BBz CART cells (Fig. 2A ,2B and2C ). - . The cytotoxic function of anti-HER2 CAR-T cells was further investigated to illustrate antigen engagement and CAR-T cell activation. After co-culture of anti-HER2 CAR-T cells with either SK-OV-3 or MDA-MB-468 tumor cell lines, it was observed that both hHD-Dz and hH8-BBz CAR-T cells effectively lysed the SK-OV-3 tumor cells, and hHD-Dz CAR-T cells showed a much different lytic cytotoxicity function from the hH8-BBz CAR-T cells (
Fig. 2D ). - . The phenotype and exhaustion marker expression of both anti-HER2 CAR-T cells and mock T cells were analyzed after a 7-day period of cell expansion (
Fig. 3 ). - . The hHD-Dz, hH8-BBz CAR-T and mock T cells showed similar percentage of CD4+ or CD8+ T cells (
Fig. 3A ). Although comparable percentage of effector memory T (TEM, CD45RO+ CD62L-) was observed in the hHD-Dz and hH8-BBz CAR-T cells, the hHD-Dz CAR-T cells showed a higher percentage of central memory T cells (TCM, CD45RO+ CD62L+) than the hH8-BBz CAR-T cells (Fig. 3A ). - . The expression pattern of inhibitory receptors, including PD-1, CTLA-4, TIM3 and LAG3, was assessed for the anti-HER2 CAR-T cells (
Fig. 3B ) in the present invention. - . It was showed that there were -10% less PD-1 or LAG3 positive cells in the hHD-Dz CAR-T cells than in the hH8-BBz CAR-T cells. In terms of TIM3 and CTLA-4 positive cells, a similar percentage was observed in the hHD-Dz and the hH8-BBz CAR-T cells (
Fig. 3B ). - . The time-course of anti-HER2 CAR expression was further explored in the present invention. Although there was a decrease of CAR expression within 96 h, the CAR expression reached to >90% after additional 48 h (
Fig. 3C ). - . Overall, the above results suggested that the dectin-1 signaling domain in the novel CAR-T cells may result in distinct phenotype and exhaustion marker expression, and discrete T cell proliferation potential.
- . Using NSG mice bearing xenograft SK-OV-3-LUc tumor cells, in vivo antitumor activity of the anti-HER2 CAR-T cells (the hH8-BBz or hHD-Dz CAR-T cells) was further investigated in the present invention. Overall survival and tumor volume were evaluated (
Fig. 4 ). Treatment with the anti-HER2 CAR-T cells resulted in a delayed tumor progression compared to the mock T cell treated mice (Fig. 4A ), and the anti-HER2 CAR-T cell groups at least doubled the median survival of tumor bearing mice (Fig. 4B ). The log rank (Mantel-Cox) test demonstrated a statistically significant difference in the survival rates between either anti-HER2 CAR-T cell group and mock T cell group. Moreover, 100% of mice in the hHD-Dz CAR-T cell group were alive by day 55, and the hH8-BBz CAR-T group showed longer overall survival (Fig. 4B ). - . The embodiment further provides a costimulatory signaling domain of a chimeric antigen receptor, wherein the costimulatory signaling domain comprises an RD-1 intracellular domain.
- . Further, the costimulatory signaling domain comprises CD3ζ.
- . Further, the RD-1 intracellular domain comprises an amino acid sequence of SEQ ID NO:1 or an amino acid sequence having not less than 90% identity with SEQ ID NO:1.
- . Further, the costimulatory signaling domain further comprises one or more of CD3, CD4, CD8, FcR, DAP10, DAP12, CD27, CD28, CD137, CD134, ICOS, OX40, CD30, CD40, PD-1, LFA-1, CD2, CD7, LIGHI, NKG2C, B7-H3, CD83-specific binding ligand, CDS, ICAM-1, GITR, BAFFR, HVEM (IGHTR), SLAMF7, NKp80 KLRE1, CD160, CD19, CD83, IL-2Rβ, IL-Rγ, IL-7Rα, ITGA4, VLA1, CD49α, ITGA4, IA4, CD49D, ITGA6, LA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11α, LFA-1, ITGAM, CDIIB, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7 TAFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96(Tactile), CEACAM1 CRTAM, Ly9 (CD229), D160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108 SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAME8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76 PAG/Cbp, NKp4, NWKp30, NKp46 and NKG2D.
- . The embodiment further provides a chimeric antigen receptor comprising the above-mentioned costimulatory signaling domain.
- . Further, the chimeric antigen receptor comprises an antigen recognition domain, a CD8α hinge region, a transmembrane domain, an RD-1 intracellular domain and CD3ζ which are connected in sequence.
- . Further, an amino acid sequence comprised in the transmembrane domain is capable of anchoring the chimeric antigen receptor to a cell membrane.
- . Further, the transmembrane domain comprises an RD-1 transmembrane domain.
- . Further, the RD-1 transmembrane domain comprises an amino acid sequence of SEQ ID NO:2 or an amino acid sequence having not less than 90% identity with SEQ ID NO:2.
- . Preferably, the antigen recognition domain is a HER2 binding domain.
- . Further, the chimeric antigen receptor comprises an amino acid sequence of SEQ ID NO:5.
- . Preferably, the antigen recognition domain is a CD19 binding domain.
- . Further, the chimeric antigen receptor comprises an amino acid sequence of SEQ ID NO:6.
- . The embodiment further provides a synthesis method of the above-mentioned chimeric antigen receptor, wherein the method comprises the following steps: step (1) synthesizing a gene sequence of RD-1-CD3ζ; step (2) synthesizing a gene sequence of the chimeric antigen receptor.
- . Further, the step (2) specifically comprises: first using primers F1 and R1 to expand a bound gene sequence of the antigen recognition domain and the CD8α hinge region, then using primers F2 and R2 to expand the gene sequence of RD-1-CD3ζ, and finally using the bound gene sequence of the antigen recognition domain and the CD8α hinge region as well as the gene sequence of RD-1-CD3ζ as templates and using F1 and R2 as primers to synthesize the gene sequence of the chimeric antigen receptor.
- . Further, the primer F1 is shown in SEQ ID NO:7, R1 is shown in SEQ ID NO:8, F2 is shown in SEQ ID NO:9, and R2 is shown in SEQ ID NO:10.
- . An amino acid sequence of the synthesized (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ) is SEQ ID NO:5.
- . The embodiment further provides a recombinant plasmid vector constructed by the above-mentioned chimeric antigen receptor and an expression vector.
- . Further, the expression vector is a pCLK vector.
- . The embodiment further provides a construction method of the above-mentioned recombinant plasmid vector, wherein the construction method comprises: using Mlu I and Spe I as restriction sites to connect genes of the chimeric antigen receptor with the expression vector, and thus to obtain the recombinant plasmid vector.
- . The embodiment further provides an immune cell modified by the above-mentioned chimeric antigen receptor.
- . Further, the immune cell is T lymphocyte.
- . Further, the immune cell also includes one or more of B lymphocyte, K lymphocyte and NK lymphocyte.
- . The embodiment further provides a method for obtaining the above-mentioned immune cell, wherein the method comprises the following steps: using Mlu I and Spe I as restriction sites to connect genes of the chimeric antigen receptor with an expression vector, and thus to obtain a recombinant plasmid vector; transfecting the recombinant plasmid vector and packaging plasmids together into cultured cells for culturing, thus to obtain recombinant virus particles; and using the recombinant virus particles to modify the immune cell.
- . Further, method of the modification comprises: using a virus vector system or non-virus vector system.
- . Further, the virus vector system includes one or more of a retroviral vector, a lentiviral vector, an adenovirus vector, an adeno-associated virus vector and a sendai virus vector.
- . Further, the non-virus vector system includes one or more of a transposon system, a CRISPR gene editing system, a TALEN system, a liposome transfection system and an electrotransfection system.
- . The purpose of the present invention is to further provide an application of the above-mentioned immune cell in preparation of an antitumor drug composition.
- . Further, the antitumor drug composition further comprises a chemical drug.
- . Further, the chemical drug includes cyclophosphamide and/or fludarabine.
- . Further, the antitumor drug composition is an antitumor drug against breast cancer and/or ovarian cancer.
- . The embodiment further provides a composition comprising the above-mentioned chimeric antigen receptor, wherein the composition further comprises one or more of a β-glucan receptor, Syk, CR3 and CD11b bound to the costimulatory signaling domain.
- . The primers used for obtaining CAR genes in the embodiment are shown in Table 1:
-
-
- (1)
Step 1, gene synthesis: synthesizing a full length of an RD-1 (TM+cytoplasmic)-CD3ζ fragment. - (2) Step 2, synthesizing primers, and obtaining a fused fragment of (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ) by an overlapping PCR method, which specifically comprises the following two steps:
- (2.1) Expanding (anti-HER2 scFV)-(CD8α hinge) using primers F1 and R1; and expanding (RD-1TM+Cytoplasmic)-(CD3ζ) using primers F2 and R2.
- (2.2) Using (anti-HER2 scFV)-(CD8α hinge) and (RD-1TM+Cytoplasmic)-(CD3ζ) as templates and using F1 and R2 as primers to obtain full-length CAR genes by PCR.
- . An amino acid sequence of the synthesized (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ) is SEQ ID NO:5.
-
- (1)
Step 1, gene synthesis: synthesizing a full length of an RD-1 (TM+cytoplasmic)-CD3ζ fragment. - (2) Step 2, designing primers, and obtaining a fused fragment of (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ) by an overlapping PCR method, which specifically comprises the following two steps:
- (2.1) Expanding (anti-HER2 scFV)-(CD8α hinge) using primers F1 and R1; and expanding (RD-1TM+Cytoplasmic)-(CD3ζ) using primers F2 and R2;
- (2.2) Using (anti-HER2 scFV)-(CD8α hinge) and (RD-1TM+Cytoplasmic)-(CD3ζ) as templates and using F1 and R2 as primers to obtain full-length CAR genes by PCR.
- (3)
Step 3, using Mlu I and Spe I as restriction sites to connect the CAR genes synthesized by the above steps with a PCLK vector, and thus to obtain a CAR-PCLK plasmid vector. -
- (1) Loading novel 2nd generation CAR genes (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ) with chimeric antigen receptor genes (the structural schematic diagram is shown in
Fig. 5 ) and conventional 2nd generation CAR genes (anti-HER2 scFV)-(CD8α hinge+TM)-(4-1BB)-(CD3ζ) (the structural schematic diagram is shown inFig. 5 ) into the lentiviral vector PCLK which is co-transfected into T cells together with two helper vectors psPAX2 and pMD2.G, resulting in respective packaged virus particles which is concentrated to obtain high-concentration lentiviral vector through centrifugation. - (2) Isolating lymphocytes by density gradient centrifugation, and stimulating the lymphocytes with a CD3 antibody (1 ug/ml) and IL-2 (100 IU/ml). After one day, collecting the lymphocytes to perform virus transfection, culturing the lymphocytes for 48 h, and collecting the transfected lymphocytes.
- (3) Using a specific antibody which recognizes antibody Fab fragments to perform a flow cytometry assay on the collected virus-transfected lymphocytes.
- .
Fig. 6 is an expression assay of a human T cell transfected by the conventional 2nd generation CAR genes, wherein the primary antibody used is a biotin-labeled goat anti-mouse Fab monoclonal antibody, and the secondary antibody used is a PE-labeled anti-streptavidin antibody (for flow cytometry). The first lane is a T cell transfected with empty virus, and the second lane is a T cell transfected with CAR genes. (InFig. 2 , hH8-BBz represents the conventional 2nd generation CAR genes (anti-HER2 scFV)-(CD8α hinge+TM)-(4-1BB)-(CD3ζ)). - .
Fig. 7 is an expression assay of a human T cell transfected by the novel 2nd generation CAR genes, wherein the primary antibody used is a biotin-labeled goat anti-mouse Fab monoclonal antibody, and the secondary antibody used is a PE-labeled anti-streptavidin antibody (for flow cytometry). The first lane is a T cell transfected with empty virus, and the second lane is a T cell transfected with CAR genes. (InFig. 3 , hHD-Dz represents the novel 2nd generation CAR genes (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ)). - . It is confirmed by flow cytometry assays that both novel and conventional 2nd generation CAR molecules are efficiently expressed on surface of lymphocytes under the same MOI (multiplicity of infection) virus transfection effect.
-
- Conventional 2nd generation CAR-T cells: (anti-HER2 scFV)-(CD8α hinge+TM)-(4-1BB)-(CD3ζ)-T cells
- Novel 2nd generation CAR-T cells: (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ)-T cells
- (1) Respectively measuring the killing effect of the two kinds of T cells on HER2 positive tumor cells SKOV3 (human ovarian cancer cells) by RTCA (RealTime Cellular Analysis), and the measurement results are shown in
Fig. 2D . (InFig. 2D , hH8-BBz represents the conventional 2nd generation CAR-T cells; and hHD-Dz represents the novel 2nd generation CAR-T cells). - (2) Respectively measuring cytokine secretion of the two kinds of CAR-T cells targeting to HER2 positive tumor cells SKOV3 (human ovarian cancer cells) and HER2 negative tumor cells MDA-MB-468 (human breast cancer cells) by ELISA, and the measurement analysis results are shown in
Fig. 8. Fig. 8 clearly shows that more cytokine (IFNγ) is secreted to the HER2 positive tumor cells SKOV3 by the novel 2nd generation CAR-T cells than by the conventional 2nd generation CAR-T cells. (InFig. 8 , hH8-BBz represents the conventional 2nd generation CAR genes (anti-HER2 scFV)-(CD8α hinge+TM)-(4-1BB)-(CD3ζ); and hHD-Dz represents the novel 2nd generation CAR genes (anti-HER2 scFV)-(CD8α hinge)-(RD-1TM+Cytoplasmic)-(CD3ζ)).
- (1) Respectively measuring the killing effect of the two kinds of T cells on HER2 positive tumor cells SKOV3 (human ovarian cancer cells) by RTCA (RealTime Cellular Analysis), and the measurement results are shown in
- . A typical CAR mainly consists of three key components, including a single-chain fragment variable (scFv) to recognize antigen, a hinge and transmembrane domain (TM), such as CD3, CD28 or CD8 protein, and intracellular signaling domains (ICDs), such as CD3ζ or FcRy. The CAR includes one or more intracellular costimulatory signaling domains, such as CD28, 4-1BB, CD27, OX40, ICOS, DAP10, IL-15Rα, MyD88/CD40 and TLR2, to transmit activation signals.
- . It has been showed that different TMs and/or ICDs affect T cell expansion, persistence and other functions. Recently, several 2nd generation CARs have been tested in patients with solid tumors, such as metastatic colorectal cancers and sarcomas. The results from these trials were far from exciting compared with that achieved in treating hematological malignancies. Therefore, exploring different costimulatory domains may provide a new approach to improve antitumor effects of CAR-T cells in the solid tumors.
- . In the present invention, CD19 or HER2-targeting scFv domains were coupled to 4-1BB or dectin-1 signaling ICDs by our experiment team to construct four different 2nd generation CARs. Experiment data revealed that the novel CAR design influenced T cell functions through dectin-1 costimulation in both in vitro and in vivo experiments, such as enhanced cytokine secretion and lytic capacity, reduced exhaustion potential, and increased cell expansion and distinct antitumor activity.
- . In the present invention, we confirmed previous study results showing enhanced CAR-T cell functions with 4-1BB costimulatory signaling domains. Interestingly, in vitro T cell functions (e.g. increased cytokine production) of the hHD-Dz CAR-T cells are comparable to the 4-1BB based, and both are superior to the mock T cells. As to the HER2 specific CAR-T cells, the IFN-γ secretion of the hHD-Dz CAR-T cells was higher than the hH8-BBz, suggesting possible predominantly Th1 phenotype; while the Hh8-bbz CAR-T cells released more TNF-α, consistent with Th1/Th2 phenotype. Similar cytokine production pattern by the anti-CD19 CAR-T cells indicated comparable phenotype irrespective to the specific costimulatory signaling domain employed. In the RTCA (real-time cytotoxicity assays), we illustrated the cytotoxic ability of the hHD-Dz CAR-T cells, superior to the hH8-BBz CAR-T cells. The above results may suggest that the dectin-1 costimulation provides a new mechanistic approach in CAR-T cell immunotherapy in treating solid tumors.
- . Due to the immune resistance and T cell exhaustion, one of the biggest challenges in CAR-T cell therapy for solid tumors is the inhibition of tumor microenvironment. However, it has been shown in studies that different T cell phenotype may play an important role in the antitumor immunity, for example, TCM cells are more important than TEM cells in the adoptive immunotherapies. In the present invention, we have found that more TCM and distinct exhaustion marker expression in the hHD-Dz CAR-T cells may suggest that the new CAR-T cells can be less influenced by the tumor immunosuppressive microenvironment through the dectin-1 costimulatory signaling in the solid tumors.
- . In addition, we demonstrated the distinct antitumor effects of the 2nd generation CAR-T cells through either dectin-1 or 4-1BB costimulation in the established tumor xenograft model. However, the CARs with the different costimulatory signaling domains here showed discrete antitumor activity trend on in vivo survival rate. The hHD-Dz CAR-T cells showed increased effector functions at early time points, and the hH8-BBz CAR-T cells demonstrated a later antitumor activity. These observations suggested that different costimulatory signaling domains may result in distinct T cell phenotype.
- . The embodiments of the present invention are described above in combination with drawings, but the present invention is not limited to the aforementioned specific embodiments. The aforementioned embodiments are merely illustrative and not limiting. For those of ordinary skill in the art, many forms can be made under the teaching of present invention without departing from the spirit of the present invention and the scope of the claims, all of which shall fall within the protection scope of the present invention.
-
- . Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO,Stetler-Stevenson M, etal.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2015, 33(6): 540-549.
- . Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. The New England journal of medicine 2016, 374(10): 998.
- . Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. The LancetOncology 2020, 21(2): e104-e116.
- . Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.The Journal of clinical investigation 2019, 129(6): 2210-2221.
- . Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CART-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. The NewEngland journal of medicine 2019, 380(18): 1726-1737.
- . Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanizedanti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. The Lancet Haematology 2019, 6(10):e521-e529.
- . Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al.Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.The New England journal of medicine 2017, 377(26): 2531-2544.
- . Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. The New England journal of medicine 2017, 377(26): 2545-2554.
- . Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. The Lancet Oncology2018.
- . Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. The Lancet Oncology2019, 20(1): 31-42.
- . Yu S, Li A, Liu Q, Li T, Yuan X, Han X, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of hematology & oncology 2017, 10(1): 78.
- . Wang Y, Luo F, Yang J, Zhao C, Chu Y. New Chimeric Antigen Receptor Design for Solid Tumors.Frontiers in immunology 2017, 8: 1934.
- . Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression inpatients receiving cell transfer therapy. Journal of immunology 2004, 173(12):7125-7130.
- . Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19CAR T cell therapy.Nature medicine 2019, 25(6): 947-953.
- . Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BBcostimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature medicine 2015, 21(6): 581-590.
- . Zimara N, Chanyalew M, Aseffa A, van Zandbergen G, Lepenies B, Schmid M, et al.Dectin-1 Positive Dendritic Cells Expand after Infection with Leishmania major Parasites and Represent Promising Targets for Vaccine Development. Frontiers inimmunology 2018, 9: 263.
- . Ariizumi K, Shen GL, Shikano S, Xu S, Ritter R, 3rd, Kumamoto T, et al. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning.The Journal of .
- . Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomares L, Gordon S, et al.The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. Journal of immunology 2002,169(7): 3876-3882.
- . Adams EL, Rice PJ, Graves B, Ensley HE, Yu H, Brown GD, et al. Differential high-affinity interaction of dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching.The Journal of pharmacology and experimental therapeutics 2008, 325(1): 115-123.
- . Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al.Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.Journal of immunotherapy 2009, 32(7): 689-702.
- . Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, SpanerDE, Maric I, et al.B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood2012, 119(12): 2709-2720.
- . Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al.Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(10):4285-4289.
- . Huang Y, Li D, Zhang PF, Liu M, Liang X, Yang X, et al. IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells.FASEB journal : official publication of the Federation of American Societies forExperimental Biology 2020, 34(1): 1768-1782.
- . Cerignoli F, Abassi YA, Lamarche BJ, Guenther G, Santa Ana D, Guimet D, et al. Invitro immunotherapy potency assays using real-time cell analysis. PloS one 2018,13(3): e0193498.
- . Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nature reviews Immunology 2009, 9(7): 465-479.
- . Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, et al. Genetically engineered T cells for cancer immunotherapy. Signal transduction and targeted therapy 2019, 4: 35.
- . Ying Z, He T, Wang X, Zheng W, Lin N, Tu M, et al. Parallel Comparison of 4-1BB orCD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma. Molecular therapy oncolytics 2019, 15: 60-68.
- . Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, et al. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype. Human gene therapy 2018, 29(5): 626-639.
- . Xia AL, Wang XC, Lu YJ, Lu XJ, Sun B. Chimeric-antigen receptor T (CAR-T) celltherapy for solid tumors: challenges and opportunities. Oncotarget 2017, 8(52):90521-90531.
- . Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer discovery 2013, 3(4): 388-398.
- . Zolov SN, Rietberg SP, Bonifant CL. Programmed .
- . Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, et al. 4-1BB enhancement of CAR T function requires NF-kappaB and TRAFs. JCI insight 2018, 3(18).
- . Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancerresearch 2006, 66(22): 10995-11004.
- . Zhang JP, Zhang R, Tsao ST, Liu YC, Chen X, Lu DP, et al. Sequential allogeneic andautologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.Blood advances 2018, 2(14): 1691-1695.
- . Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012, 1(4): 458-466.
- . Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, et al. Chimeric antigen receptor comprising ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. Journal of hematology &oncology 2013, 6: 33.
- . Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, et al. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ open 2017, 7(11): e017075.
- . Nair S, Wang JB, Tsao ST, Liu Y, Zhu W, Slayton WB, et al. Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Ralpha Signaling.Current gene therapy 2018.
- . Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer discovery 2017, 7(11):1306-1319.
- . Lai Y, Weng J, Wei X, Qin L, Lai P, Zhao R, et al. Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells. Leukemia 2018, 32(3): 801-808.
- . Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, et al. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. Molecular therapy: the journal of the American Society of GeneTherapy 2018, 26(4): 976-985.
- . Zhang CC, Wang Z, Yang Z, Wang ML, Li SQ, Li YY, et al. Phase I Escalating-DoseTrial of CAR-T Therapy Targeting CEA(+) Metastatic Colorectal Cancers. MolecularTherapy 2017, 25(5): 1248-1258.
- . Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. Journalof clinical oncology: official journal of the American Society of Clinical Oncology 2015,33(15): 1688-1696.
- . Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, et al.Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The NewEngland journal of medicine 2015,373(11): 1040-1047.
- . Wei G, Ding L, Wang J, Hu Y, Huang H. Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia.Experimental hematology & oncology 2017, 6: 10.
- . Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature 2017,545(7655): 423-431.
- . Brown GD, Willment JA, Whitehead L. C-type lectins in immunity and homeostasis.Nature reviews Immunology 2018, 18(6): 374-389.
- . Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, MiT, et al. Bioengineering Tcells to target carbohydrate to treat opportunistic fungal infection. Proceedings of theNational Academy of Sciences of the United States of America 2014, 111(29):10660-10665.
- . Brown GD, Crocker PR. Lectin Receptors Expressed on Myeloid Cells. Microbiologyspectrum 2016, 4(5).
- . Chiba S, Ikushima H, Ueki H, Yanai H, Kimura Y, Hangai S, et al. Recognition of tumor cells byDectin-1 orchestrates innate immune cells for anti-tumor responses. eLife2014, 3: e04177.
- . Kaisar MMM, Ritter M, Del Fresno C, Jonasdottir HS, van der Ham AJ, Pelgrom LR, etal.Dectin-1/2-induced autocrine PGE2 signaling licenses dendritic cells to prime Th2responses. PLoS biology 2018, 16(4): e2005504.
- . Zhao Y, Chu X, Chen J, Wang Y, Gao S, Jiang Y, et al. Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. Naturecommunications 2016, 7: 12368.
- . Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer.Annual review of medicine 2015, 66: 111-128.
- . Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, et al. AMultifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.Cancer research 2017, 77(6):1296-1309.
- . Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, etal. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PloS one2013, 8(4): e60031.
- . Abken H. Driving CARs on the Highway to Solid Cancer: Some Considerations on theAdoptive Therapy with CAR T Cells. Human gene therapy 2017, 28(11): 1047-1060.
- . Bagley SJ, O'Rourke DM. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. Pharmacology & therapeutics 2019: 107419.
- . Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE,et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(27): 9571-9576.
- . Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.The Prostate2014, 74(3): 286-296.
- . Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112(6):2261-2271.
- . Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specificadoptive immunotherapy for lymphoma using a chimeric antigen receptor with bothCD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119(17): 3940-3950.
- . Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, et al. Th17cells are long lived and retain a stem cell-like molecular signature. Immunity 2011,35(6): 972-985.
- . Zhang PF, Huang Y, Liang X, Li D, Jiang L, Yang X, et al. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.FASEB journal: official publication ofthe Federation of American Societies for Experimental Biology 2020, 34(8):11185-11199.
- . Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory Tcell subset with stem cell-like properties.Nature medicine 2011, 17(10): 1290-1297.
Claims (21)
- A chimeric antigen receptor, comprising an extracellular domain, a transmembrane domain and an intracellular domain, wherein the transmembrane domain and the intracellular domain of the chimeric antigen receptor form a costimulatory signaling domain, and the costimulatory signaling domain comprises a full length or a fragment of an amino acid sequence encoding a reverse dectin-1.
- The chimeric antigen receptor according to claim 1, wherein the extracellular domain comprises a single-chain antibody targeting to CD19 or HER2.
- The chimeric antigen receptor according to claim 2, wherein the chimeric antigen receptor further comprises a CD8α hinge region, a reverse dectin-1 transmembrane domain, a reverse dectin-1 intracellular signaling domain and a CD3ζ intracellular signaling domain which are connected in sequence.
- The chimeric antigen receptor according to claim 1, wherein the amino acid sequence encoding the reverse dectin-1 is shown in SEQ ID NO:3.
- The chimeric antigen receptor according to claim 3, wherein an amino acid sequence encoding the reverse dectin-1 transmembrane domain is shown in SEQ ID NO:2.
- The chimeric antigen receptor according to claim 3, wherein an amino acid sequence encoding the reverse dectin-1 intracellular signaling domain is shown in SEQ ID NO:1.
- A lentiviral vector comprising the chimeric antigen receptor according to any one of claims 1-6.
- The lentiviral vector according to claim 7, wherein the lentiviral vector comprises pCLK, psPAX2 or pMD2.0G.
- A CAR-T cell, wherein expressing the chimeric antigen receptor according to any one of claims 1-6.
- An antitumor drug, comprising the CAR-T cell according to claim 9 and a pharmaceutically acceptable excipient and/or adjuvant.
- The antitumor drug according to claim 10, wherein the tumor comprises hematological tumors and solid tumors.
- The antitumor drug according to claim 10, wherein the tumor comprises large B-cell lymphoma, B-cell lymphoma, non-Hodgkin lymphoma, myelogenous leukemia, lymphoblastic leukemia, breast cancer, gastric cancer, esophageal cancer or ovarian cancer.
- Use of the CAR-T cell according to claim 9 in preparation of an antitumor drug.
- The use according to claim 13, wherein the CAR-T cell can stimulate secretion of effector cytokine.
- The use according to claim 14, wherein the effector cytokine comprises IFN-γ, TNF-α and IL-6.
- The use according to claim 13, wherein the CAR-T cell, upon being stimulated, display phenotype of a central memory T cell.
- The use according to claim 13, wherein the tumor comprises hematological tumors and solid tumors.
- The use according to claim 13, wherein the tumor comprises large B-cell lymphoma, B-cell lymphoma, non-Hodgkin lymphoma, myelogenous leukemia, lymphoblastic leukemia, breast cancer, gastric cancer, esophageal cancer or ovarian cancer.
- A synthesis method for the chimeric antigen receptor according to any one of claims 1-6, comprising the following steps: (1) synthesizing a gene sequence of the reverse dectin-1 transmembrane domain - reverse dectin-1 intracellular domain or a gene sequence of the reverse dectin-1 transmembrane domain - CD3ζ intracellular signaling domain; (2) synthesizing primers according to a target, and synthesizing a gene sequence of the chimeric antigen receptor by an overlapping PCR method.
- The synthesis method according to claim 19, wherein the step (2) specifically comprises: first using primers F1 and R1 to expand a bound gene sequence of the extracellular domain and the CD8α hinge region, then using primers F2 and R2 to expand the gene sequence of the reverse dectin-1 transmembrane domain - CD3ζ intracellular signaling domain, and finally using the bound gene sequence of the extracellular domain and the CD8α hinge region as well as the gene sequence of the reverse dectin-1 transmembrane domain - CD3ζ intracellular signaling domain as templates and using F1 and R2 as primers to synthesize the gene sequence of the chimeric antigen receptor.
- The synthesis method according to claim 20, wherein the primer F1 is shown in SEQ ID NO:7, R1 is shown in SEQ ID NO:8, F2 is shown in SEQ ID NO:9, and R2 is shown in SEQ ID NO:10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010090749.5A CN113248620A (en) | 2020-02-13 | 2020-02-13 | Co-stimulation signal structure domain of chimeric antigen receptor and application thereof |
PCT/CN2021/075544 WO2021160038A1 (en) | 2020-02-13 | 2021-02-05 | Chimeric antigen receptor and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4105240A1 true EP4105240A1 (en) | 2022-12-21 |
EP4105240A4 EP4105240A4 (en) | 2024-05-29 |
Family
ID=76876004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21753498.1A Pending EP4105240A4 (en) | 2020-02-13 | 2021-02-05 | Chimeric antigen receptor and use thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4105240A4 (en) |
JP (1) | JP7466231B2 (en) |
CN (1) | CN113166274B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894704B (en) * | 2021-09-24 | 2023-12-26 | 四川大学 | Antibody specifically targeting tumor EpCAM antigen and application thereof |
CN114835820B (en) * | 2022-04-14 | 2023-01-06 | 呈诺再生医学科技(珠海横琴新区)有限公司 | Chimeric Fc receptor for genetically modified pluripotent stem cells and natural killer cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
EP3544618A4 (en) | 2018-01-11 | 2020-02-12 | Innovative Cellular Therapeutics Inc. | Modified cell expansion and uses thereof |
JP2021529552A (en) | 2018-07-19 | 2021-11-04 | オンコホスト リミテッド | IL-31 Improves Efficacy of Macrophage-Based Adoptive Cell Therapy for Cancer |
-
2021
- 2021-02-05 JP JP2022548605A patent/JP7466231B2/en active Active
- 2021-02-05 CN CN202180000930.5A patent/CN113166274B/en active Active
- 2021-02-05 EP EP21753498.1A patent/EP4105240A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4105240A4 (en) | 2024-05-29 |
JP2023515364A (en) | 2023-04-13 |
CN113166274B (en) | 2023-05-02 |
CN113166274A (en) | 2021-07-23 |
JP7466231B2 (en) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xie et al. | Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments | |
EP3564266A1 (en) | Novel chimeric antigen receptor and use thereof | |
AU2015315199B2 (en) | Chimeric receptors and uses thereof in immune therapy | |
CA2926267C (en) | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors | |
Hosseini et al. | Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy | |
Atanackovic et al. | Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma | |
JP2017530694A5 (en) | ||
EP4105240A1 (en) | Chimeric antigen receptor and use thereof | |
EP3568416A1 (en) | Chimeric antigen receptors targeting tim-1 | |
CN112218651A (en) | Immunopotentiating RNA for combination with chimeric antigen receptor therapy | |
US20200268797A1 (en) | Gamma delta t cells and uses thereof | |
Zuo et al. | Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers | |
KR20230129979A (en) | Dendritic cell activation chimeric antigen receptor and uses thereof | |
WO2018140960A1 (en) | Improved antibody-coupled t cell receptor constructs and therapeutic uses thereof | |
WO2022133056A9 (en) | Expanded and stimulated natural killer cells | |
Liang et al. | Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain | |
EP3551294B1 (en) | Improved nk-based cell therapy | |
CA3174074A1 (en) | .gamma..delta. t cells and uses thereof | |
WO2021160038A1 (en) | Chimeric antigen receptor and use thereof | |
CA3228635A1 (en) | Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacy | |
KR20210014688A (en) | Chimeric antigen receptor T cell therapy | |
Guo et al. | Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity | |
EP3191109B1 (en) | A cell population for use in treating cancer | |
Sefrin | Sensitization of tumor cells for T cell mediated eradication through targeted delivery of virus-derived immunogenic peptide epitopes | |
Leung | Improving the Efficacy of Double-Negative T-Cells (DNTs) Against Lung Cancer: Chimeric Antigen Receptor-Transduced DNTs as a Potential Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220825 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240430 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/02 20060101ALI20240426BHEP Ipc: A61P 35/00 20060101ALI20240426BHEP Ipc: A61K 48/00 20060101ALI20240426BHEP Ipc: A61K 35/17 20150101ALI20240426BHEP Ipc: C12N 15/12 20060101ALI20240426BHEP Ipc: C12N 5/10 20060101ALI20240426BHEP Ipc: C07K 19/00 20060101AFI20240426BHEP |